We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
-8.74%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$2.37B
AUM Growth
-$222M
Cap. Flow
+$343M
Cap. Flow %
14.48%
Top 10 Hldgs %
48.21%
Holding
122
New
26
Increased
34
Reduced
9
Closed
19

Top Buys

Rank Stock Value
1
QURE icon
uniQure
QURE
+$66.1M
2
BDTX icon
Black Diamond Therapeutics
BDTX
+$51.6M
3
SDGR icon
Schrodinger
SDGR
+$33.9M
4
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$30.5M
5
PYPL icon
PayPal
PYPL
+$26.5M

Top Sells

Rank Stock Value
1
MRNA icon
Moderna
MRNA
+$37M
2
XNCR icon
Xencor
XNCR
+$18.9M
3
BNTX icon
BioNTech
BNTX
+$15.6M
4
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$11M
5
BABA icon
Alibaba
BABA
+$10.4M

Sector Composition

Rank Sector Weight
1 Healthcare 69.42%
2 Consumer Discretionary 14.34%
3 Miscellaneous 11.65%
4 Financials 1.8%
5 Technology 1.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FOLD
51
CALL
DELISTED
Amicus Therapeutics
FOLD
$9.24M 0.39%
1,000,000
+500,000
+100% +$4.75M
DNLI icon
52
Denali Therapeutics
DNLI
$3.37B
$8.76M 0.37%
500,000
+100,000
+25% +$2.09M
STNE icon
53
StoneCo
STNE
$2.33B
$8.71M 0.37%
400,000
– –
ARAV
54
DELISTED
Aravive, Inc. Common Stock
ARAV
$8.35M 0.35%
1,450,000
+100,000
+7% +$896K
RNAC icon
55
Cartesian Therapeutics
RNAC
$248M
$8.23M 0.35%
113,788
– –
RGNX icon
56
Regenxbio
RGNX
$563M
$8.1M 0.34%
250,000
+105,000
+72% +$4.37M
TCDA
57
DELISTED
Tricida, Inc. Common Stock
TCDA
$7.92M 0.33%
360,000
– –
PRQR icon
58
ProQR Therapeutics
PRQR
$262M
$7.14M 0.3%
1,300,000
– –
ACIU icon
59
AC Immune
ACIU
$274M
$6.91M 0.29%
1,000,000
– –
HOOK
60
DELISTED
HOOKIPA Pharma
HOOK
$6.57M 0.28%
79,626
-20,873
-21% -$2.29M
CLVS
61
DELISTED
Clovis Oncology, Inc.
CLVS
$6.36M 0.27%
1,000,000
– –
MLCO icon
62
CALL
Melco Resorts & Entertainment
MLCO
$1.92B
$6.2M 0.26%
+500,000
New +$9.56M
AGEN
63
Agenus
AGEN
$312M
$6.13M 0.26%
127,375
– –
AAL icon
64
CALL
American Airlines Group
AAL
$8.67B
$6.09M 0.26%
500,000
– –
MRUS
65
DELISTED
Merus
MRUS
$6.05M 0.26%
500,000
– –
ALEC icon
66
Alector
ALEC
$239M
$6.03M 0.26%
250,000
+25,000
+11% +$637K
NERV icon
67
Minerva Neurosciences
NERV
$198M
$6.02M 0.25%
125,000
– –
REPL icon
68
Replimune Group
REPL
$1.24B
$5.98M 0.25%
600,000
– –
TBIO
69
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$5.98M 0.25%
600,000
-50,000
-8% -$410K
ADVM
70
DELISTED
Adverum Biotechnologies
ADVM
$5.86M 0.25%
+60,000
New +$7M
STOK icon
71
Stoke Therapeutics
STOK
$1.87B
$5.72M 0.24%
+250,000
New +$6.18M
ADPT icon
72
Adaptive Biotechnologies
ADPT
$3.86B
$5.56M 0.23%
200,000
+50,000
+33% +$1.39M
AXDX
73
DELISTED
Accelerate Diagnostics
AXDX
$5M 0.21%
60,000
– –
CYCN
74
DELISTED
Cyclerion Therapeutics
CYCN
$4.93M 0.21%
93,079
+25,000
+37% +$1.78M
SPRO icon
75
Spero Therapeutics
SPRO
$65.8M
$4.65M 0.2%
576,000
+76,000
+15% +$670K
1 2
3
4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q1 2020 Portfolio in Review

As of Q1 2020, Artal Group held 122 positions worth $2.37B, down 8.6% from $2.59B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Artal Group deployed $343M of net new capital in Q1 2020, opening 26 new positions and adding to 34 existing holdings. Its largest new stake was uniQure: 1,150,000 shares worth $54.6M.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, up from 63% a quarter earlier, followed by Consumer Discretionary and Miscellaneous.

On the sell side, the largest reduction was Moderna, an estimated $37M trimmed.

  • Artal Group's largest Q1 2020 buy was uniQure: 1,150,000 shares worth $54.6M.
  • Artal Group added most to Deciphera Pharmaceuticals, Inc. Common Stock in Q1 2020, an estimated $30.5M increase.
  • Artal Group's biggest Q1 2020 reduction was Moderna, cutting an estimated $37M.
  • Artal Group fully exited Xencor in Q1 2020, selling an estimated $18.9M.
  • Artal Group's ten largest holdings make up 48% of its $2.37B portfolio in Q1 2020.
  • Artal Group opened 26 new positions and closed 19 in Q1 2020.
  • Artal Group's portfolio value fell 8.6% quarter-over-quarter to $2.37B.

Based on Artal Group's 13F filing for Q1 2020, filed 14 May 2020.